王峰博士 研究员 博士生导师 中科院生物物理所，蛋白质与多肽药物所重点实验室副主任，研究组长
研究方向：（1）蛋白质工程及大分子药物开发；（2）新型抗生素的研发；（3）化学生物学/合成生物学
电子邮件：wangfeng@ibp.ac.cn
电话：
通讯地址：北京市朝阳区大屯路15号（100101）
英文版个人网页：http://english.ibp.cas.cn/ibp_pi/W/201710/t**_185263.html







简历： 　　1993 - 1998 就读于中国科技大学化学物理系，获理学学士学位
　　1998 - 2000 就读于美国Northwestern University化学系，获硕士学位
　　2003 - 2007 就读于美国TEXAS A&M UNIVERSITY化学系，获生物化学博士学位
　　2007 - 2012 美国诺华制药基因药物研究所(Genomics Institute of the Novartis Research Foundation)/美国斯克利普斯研究所(The Scripps Research Institute) ，博士后
　　2012 - 2017 美国加州生物医药研究所，首席研究员 (Principal Investigator) / 大分子药物及传染病课题组负责人
　　2018 - 至今 中国科学院生物物理所，研究员

获奖及荣誉：
社会任职：
研究方向： 　　1. 蛋白质工程及大分子药物开发：
　　新一代人源抗体筛选技术的研究；
　　特殊抗体骨架及进化机理的研究；
　　双功能、多功能抗体、抗体偶联制备新技术的开发；
　　新型长效融合蛋白技术的研究。
　　2. 抗结核药物的研发：
　　通过高通量化合物筛选新的抗结核药物；
　　新筛选条件和方法的研究，药物作用机理的研究；
　　以药物靶标结构为基础的药物设计；
　　3. 化学生物学/合成生物学：
　　在不同物种中基于基因密码子扩展的蛋白质标记新方法的研究；
　　在蛋白表达层面上调控致病菌活性的方法研究；
　　含有非天然氨基酸的天然产物的生物合成方法的研究；
主要学术贡献：　　王峰博士在小分子药物筛选及生物大分子制药领域主持了大量的研发项目，并在Cell，Nature Medicine，PNAS，JEM，JACS，Angew. Chemie等国际顶级期刊发表大量研究论文，同时有多项成果已经申请全球专利。
　　在大分子制药领域，王峰博士首次发现并表征了一种全新的具有超长可变区的抗体，改变了对抗体结构、功能、进化上的传统认识。以这种新型抗体骨架为基础，王峰博士领导的课题组研发了一系列新一代抗体候选药物。
　　在传染病药物研究领域，王峰博士领导的课题组通过高通量化合物筛选方法寻找针对细胞内耐药性结核菌的抑制剂，目前已发现两种在动物模型中有效的先导化合物，其中一种已经进入临床二期试验。
　　在化学生物学、合成生物学领域，王峰课题组建立了在多种病原菌中基于基因密码子扩展的蛋白质标记新方法，实现利用非天然氨基酸蛋白修饰研究细胞中的蛋白质相互作用。

承担项目情况：
代表论著： 　　1. Yuhan Zhang, Changming Fang, Rongsheng E. Wang, Ying Wang, Hui Guo, Chao Guo, Lijun Zhao, Shuhong Li, Xia Li, Peter G. Schultz, Yu J. Cao, and Feng Wang*, A tumor-targeted immune checkpoint blocker. Proc. Natl. Acad. Sci. U S A., 2019 116 (32) 15889-15894.
　　2. Harbut MB, Yang BY, Liu RH, Yano T, VilchHze C, Cheng B, Lockner J, Guo H, Yu CG, Franzblau SG, Petrassi M, Jacobs WRJ, Rubin H, Chatterjee AK, and Feng Wang*, Small Molecules Targeting Mycobacterium tuberculosis Type II NADH Dehydrogenase Exhibit Antimycobacterial Activity. Angew Chem. Int. Ed. Engl. 2018, 57, 3478 –3482.
　　3. Na Chen, Siqi Xu, Yuhan Zhang, Feng Wang*, Animal protein toxins: origins and therapeutic applications. Biophys Rep 2018, 4(5):233–242.
　　4. Du JJ, Cao Y, Liu Y, Wang Y, Zhang Y, Fu GS, Zhang YH, Lu L, Luo XZ, Kim CH, Schultz PG, Feng Wang*, Engineering bifunctional antibodies with constant region fusion architectures. J. Am. Chem. Soc., 2017,139, 18607-18615.
　　5. Renhe Liu, Xiaoxuan Lyu, Sarah M Batt, Mei-Hui Hsu, Michael B Harbut, Catherine Vilchèze, Bo Cheng, Kehinde Ajayi, Baiyuan Yang, Yun Yang, Hui Guo, Changyou Lin, Fei Gan, Chen Wang, Scott G. Franzblau, William R. Jacobs Jr., Gurdyal S. Besra, Eric F. Johnson, Mike Petrassi, Arnab K. Chatterjee, Klaus Fütterer, Feng Wang*, Determinants of the Inhibition of DprE1 and CYP2C9 by Antitubercular Thiophenes, Angew Chem. Int. Ed. Engl., 2017, 56，13011-13015
　　6. Xiaozhou Luo, Guangsen Fu, Rongsheng E. Wang, Xueyong Zhu, Claudio Zambaldo, Renhe Liu, Tao Liu, Xiaoxuan Lyu, Jintang Du, Weimin Xuan, Anzhi Yao, Sean A. Reed, Mingchao Kang, Yuhan Zhang, Hui Guo, Chunhui Huang, Peng-Yu Yang, Ian A. Wilson, Peter G. Schultz, and Feng Wang*, Genetically encoding phosphotyrosine and its nonhydrolyzable analog in bacteria, Nat. Chem. Biol.，2017, 13，845-849
　　7. Ying Wang, Jintang Du, Huafei Zou, Yan Liu, Yuhan Zhang, Jose Gonzalez, Elizabeth Chao, Lucy Lu, Holly Parker, Van Nguyen-Tran, Weijun Shen, Danling Wang, Peter G. Schultz, and Feng Wang*, Multi-functional Antibody Agonists Targeting Glucagon-like Peptide-1, Glucagon, and Glucose-dependent Insulinotropic Polypeptide Receptors, Angew Chem. Int. Ed. Engl., 2016, 55, 12475–12478
　　8. Yan Liu, Ying Wang, Yong Zhang, Tao Liu, Haiqun Jia, Huafei Zou, Qiangwei Fu, Yuhan Zhang, Lucy Lu, Elizabeth Chao, Holly Parker, Van Nguyen-Tran, Weijun Shen, Danling Wang, Peter G. Schultz*, and Feng Wang*, Rational Design of Dual Agonist-Antibody Fusions as Long-acting Therapeutic Hormones, ACS Chem. Biol., 2016, 11, 2991-2995
　　9. Rongsheng E. Wang, Ying Wang, Yuhan Zhang, Chase Gabrelow, Yong Zhang, Victor Chi, Qiangwei Fu, Xiaozhou Luo, Danling Wang, Sean Joseph, Kristen Johnson, Arnab Chatterjee, Timothy M. Wright, Van Nguyen-Tran, John Tejaro, Argyrios N. Theofilopoulos, Peter G. Schultz, Feng Wang*, Rational Design of a Kv1.3 Channel Blocking Antibody as a Selective Immunosuppressant, Proc. Natl. Acad. Sci. U S A., 2016, 113, 11501–11506
　　10. Xiaozhou Luo, Tao Liu, Ying Wang, Haiqun Jia, Yuhan Zhang, Dawna Caballero, Juanjuan Du, Rongsheng E. Wang, Danling Wang, Peter G. Schultz and Feng Wang*, An Epitope-Specific Respiratory Syncytial Virus Vaccine based on an Antibody Scaffold, Angew Chem. Int. Ed. Engl., 2015, 54, 14531-14534
　　11. Tao Liu, Juanjuan Du, Xiaozhou Luo, Peter G Schultz, Feng Wang*, Homogeneously modified immunoglobulin domains for therapeutic application, Curr Opin Chem Biol., 2015, 28, 66-74
　　12. Michael B. Harbut, Catherine Vilchèze, Xiaozhou Luo, Mary E. Hensler, Hui Guo, Baiyuan Yang, Arnab K. Chatterjee, Victor Nizet, William R. Jacobs Jr., Peter G. Schultz, and Feng Wang*, Auranofin exerts broad-spectrum bactericidal activities by targeting thiol-redox homeostasis, Proc. Natl. Acad. Sci. U S A., 2015, 112, 4453-4458
　　13. Tao Liu, Guangsen Fu, Xiaozhou Luo, Yan Liu, Ying Wang, Rongsheng Wang, Peter G. Schultz, and Feng Wang*, Rational design of antibody protease inhibitors, J. Am. Chem. Soc., 2015, 137, 4042-4045
　　14. Rongsheng Wang, Tao Liu, Ying Wang, Yu Cao, Jintang Du, Xiaozhou Luo, Vishal Deshmukh, Chan Hyuk Kim, Brian R. Lawson, Matthew S. Tremblay, Travis S. Young, Stephanie A. Kanzane, Feng Wang*, and Peter G. Schultz*, An immunosuppressive antibody-drug conjugate, J. Am. Chem. Soc., 2015, 137, 3229-3232
　　15. Tao Liu, Yong Zhang, Yan Liu, Ying Wang, Haiqun Jia, Mingchao Kang, Xiaozhou Luo, Dawna Caballero, Jose Gonzalez, Danling Wang, Ashley Woods, Peter G. Schultz and Feng Wang*, Functional Human Antibody CDR Fusions as Long-Acting Therapeutic Endocrine Agonists, Proc. Natl. Acad. Sci. U S A., 2015, 112, 1356-1361
　　16. Yong Zhang, Huafei Zou, Ying Wang, Dawna Caballero, Jose Gonzalez, Elizabeth Chao, Gus Welzel, Weijun Shen, Danling Wang, Peter G. Schultz and Feng Wang*, Rational Design of a Humanized Glucagon-Like Peptide-1 Receptor Agonist Antibody, Angew Chem. Int. Ed. Engl., 2015, 54, 2126-2130
　　17. Yong Zhang, Yan Liu, Ying Wang, Peter G. Schultz and Feng Wang*, Rational Design of Humanized Dual-Agonist Antibodies, J. Am. Chem. Soc., 2015, 137, 38-41
　　18. Tao Liu, Yan Liu, Ying Wang, Mitchell Hull, Peter G. Schultz, and Feng Wang*, Rational design of CXCR4 specific antibodies with elongated CDRs, J. Am. Chem. Soc., 2014, 136, 10557-60
　　19. Yong Zhang, Devrishi Goswami, Danling Wang, Tsung-Shing Andrew Wang, Shiladitya Sen, Thomas J. Magliery, Patrick R. Griffin, Feng Wang*, and Peter G. Schultz, An Antibody with a Variable Region Coiled-Coil “Knob” Domain, Angew Chem. Int. Ed. Engl., 2014, 5, 132-135
　　20. Yong Zhang, Danling Wang, Gus Welzel, Ying Wang, Peter G. Schultz, and Feng Wang*, An Antibody CDR3-Erythropoietin Fusion Protein, ACS Chem. Biol., 2013, 8, 2117-2121
　　21. Yong Zhang, Danling Wang, Lorenzo de Lichtervelde, Sophie B. Sun, Vaughn V. Smider, Peter G. Schultz, Feng Wang*, Functional Antibody CDR3 Fusion Proteins with Enhanced Pharmacological Properties, Angew Chem. Int. Ed. Engl., 2013, 52, 8295-8298
　　22. Feng Wang, Dhinakaran Sambandan, Rajkumar Halder, Jianing Wang, Sarah M. Batt, Brian Weinrick, Insha Ahmad, Pengyu Yang, Yong Zhang, John Kim, Morad Hassani, Stanislav Huszar, Claudia Trefzer, Zhenkun Ma, Takushi Kaneko, Khisi E. Mdluli, Scott Franzblau, Arnab K. Chatterjee, Kai Johnson, Katarina Mikusova, Gurdyal S. Besra, Klaus Fütterer, William R. Jacobs, Jr., and Peter G. Schultz, Identification of a small molecule with activity against drug-resistant and persistent tuberculosis, Proc. Natl. Acad. Sci. U S A., 2013, 110, E2510-E2517
　　23. Feng Wang, Damian C. Ekiert, Insha Ahmad, Wenli Yu, Yong Zhang, Omar Bazirgan, Ali Torkamani, Terje Raudsepp, Waithaka Mwangi, Michael F. Criscitiello, Ian A. Wilson, Peter G. Schultz, Vaughn V. Smider, Reshaping antibody diversity, Cell, 2013, 153, 1379-1393
　　
（资料来源：王峰研究员，2019-10-14）